Celcuity Inc. (CELC)
NASDAQ: CELC · Real-Time Price · USD
54.91
-2.52 (-4.39%)
At close: Sep 12, 2025, 4:00 PM EDT
54.51
-0.40 (-0.73%)
After-hours: Sep 12, 2025, 7:52 PM EDT
Celcuity Employees
Celcuity had 87 employees as of December 31, 2024. The number of employees increased by 32 or 58.18% compared to the previous year.
Employees
87
Change (1Y)
32
Growth (1Y)
58.18%
Revenue / Employee
n/a
Profits / Employee
-$1,709,312
Market Cap
2.33B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 87 | 32 | 58.18% |
| Dec 31, 2023 | 55 | 10 | 22.22% |
| Dec 31, 2022 | 45 | 6 | 15.38% |
| Dec 31, 2021 | 39 | 9 | 30.00% |
| Dec 31, 2020 | 30 | 3 | 11.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CELC News
- 4 days ago - Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance - GlobeNewsWire
- 17 days ago - Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program - GlobeNewsWire
- 4 weeks ago - Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call - GlobeNewsWire
- 6 weeks ago - Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst - Seeking Alpha
- 6 weeks ago - Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - Celcuity: What's Happening With CELC Stock? - Forbes